{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:38:51Z","timestamp":1791509931458,"version":"4.3.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES:<\/jats:title>\n                    <jats:p>Bivalirudin, an IV direct thrombin inhibitor, is increasingly used as an alternative anticoagulant in pediatric patients on mechanical circulatory support, with heparin failure, or for heparin-induced thrombocytopenia. Data on its use for treatment or prevention of venous or arterial thromboses in children are limited. To describe the safety of bivalirudin in critically ill children for the treatment or prevention of venous and\/or arterial thromboses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DESIGN:<\/jats:title>\n                    <jats:p>Retrospective review of patients under 18 years treated with bivalirudin between January 2019 and August 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>SETTING:<\/jats:title>\n                    <jats:p>Quaternary care Children\u2019s Hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS:<\/jats:title>\n                    <jats:p>Descriptive analyses were conducted for all patients receiving bivalirudin. Primary outcomes include bleeding and thrombotic events. Secondary outcomes included time to therapeutic levels, dosing, and the association of therapeutic laboratory goals (via Partial Thromboplastin Time Hepzyme [PTTHz] and dilute thrombin time-derived bivalirudin levels) with adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>INTERVENTION:<\/jats:title>\n                    <jats:p>None.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n                    <jats:p>\n                      A total of 261 bivalirudin encounters in 229 patients were included in the analysis (median age, 0.51 yr; interquartile range, 0.13\u20133.92 yr). The most common indication was treatment of venous thrombosis (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 133, 51%). Eighty-six bleeding events occurred in 261 encounters (33%) involving 61 of 229 patients (27%); 20 of 86 bleeding events were considered major (23.2%). Thrombotic progression or development of new thrombi occurred in 46 of 261 (17.6%) encounters (37\/229; 16% patients) with 18 of 261 experiencing both bleeding and thrombotic events. Therapeutic PTTHz\/bivalirudin levels were observed in 56.5% (26\/46) of new thromboses\/thrombotic progression and 57% (49\/86) of bleeding events. Median starting dose and dose at first therapeutic level were 0.15 and 0.2\u2009mg\/kg\/hr, respectively. Median time to achieve therapeutic anticoagulation was 0.56 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Bivalirudin, used in the setting of venous and\/or arterial thromboses, rapidly achieves therapeutic levels. While use of bivalirudin is safe, clinically relevant bleeding and thrombotic rates on bivalirudin were frequent despite therapeutic ranges. These data highlight that bivalirudin use warrants close monitoring in critically ill children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pcc.0000000000004029","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T14:00:40Z","timestamp":1787580040000},"page":"1207-1214","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Safety of Bivalirudin Use in Critically Ill Children: A Single-Center Experience"],"prefix":"10.1097","volume":"27","author":[{"given":"Dalia A.","family":"Bashir","sequence":"first","affiliation":[{"name":"Division of Critical Care Medicine, Department of Pediatrics, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Leija","sequence":"additional","affiliation":[{"name":"Pediatric Residency Program, Department of Pediatrics, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayhan N.","family":"Jhanji","sequence":"additional","affiliation":[{"name":"School of Medicine, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquelyn M.","family":"Powers","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children\u2019s Cancer and Hematology Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine I.","family":"Lemming","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Texas Children\u2019s Hospital, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Sartain","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children\u2019s Cancer and Hematology Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duy M.","family":"Dinh","sequence":"additional","affiliation":[{"name":"Division of Critical Care Medicine, Department of Pediatrics, Texas Children\u2019s Hospital, Baylor College of Medicine, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clay T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children\u2019s Cancer and Hematology Center, Houston, TX."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"R2-20261008"},{"key":"R3-20261008","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1527-3466.2005.tb00177.x","article-title":"Bivalirudin: Pharmacology and clinical applications.","volume":"23","author":"Shammas","year":"2005","journal-title":"Cardiovasc Drug Rev"},{"key":"R4-20261008","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/jocs.14458","article-title":"Heparin vs bivalirudin anticoagulation for extracorporeal membrane oxygenation.","volume":"35","author":"Kaseer","year":"2020","journal-title":"J Card Surg"},{"key":"R5-20261008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MOP.0000000000001131","article-title":"Bivalirudin in pediatric extracorporeal membrane oxygenation.","volume":"34","author":"Ryerson","year":"2022","journal-title":"Curr Opin Pediatr"},{"key":"R7-20261008","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1055\/s-0043-1772838","article-title":"Anticoagulation with intravenous direct thrombin inhibitors in pediatric extracorporeal membrane oxygenation: A systematic review of the literature.","volume":"49","author":"Kiskaddon","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"R8-20261008","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1055\/s-0044-1791534","article-title":"Intravenous direct thrombin inhibitors for acute venous thromboembolism or heparin-induced thrombocytopenia with thrombosis in children: A systematic review of the literature.","volume":"51","author":"Kiskaddon","year":"2025","journal-title":"Semin Thromb Hemost"},{"key":"R9-20261008","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1097\/PCC.0000000000002384","article-title":"Evaluation of bivalirudin as an alternative to heparin for systemic anticoagulation in pediatric extracorporeal membrane oxygenation.","volume":"21","author":"Hamzah","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"R10-20261008","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/ijlh.13780","article-title":"How to best monitor bivalirudin anticoagulant effect for ECMO and VAD-comparison of four assay methods.","volume":"44","author":"Teruya","year":"2022","journal-title":"Int J Lab Hematol"},{"key":"R11-20261008","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ajcp\/aqac131","article-title":"Monitoring direct thrombin inhibitors with calibrated diluted thrombin time vs activated partial thromboplastin time in pediatric patients.","volume":"159","author":"Hasan","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"R12-20261008","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1538-7836.2010.03975.x","article-title":"ISTH\/SSC bleeding assessment tool: A standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders.","volume":"8","author":"Rodeghiero","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R14-20261008","doi-asserted-by":"crossref","first-page":"e239535","DOI":"10.1136\/bcr-2020-239535","article-title":"Bivalirudin and thrombolytic therapy: A novel successful treatment of severe aortic arch thrombosis in a term neonate.","volume":"14","author":"Taha","year":"2021","journal-title":"BMJ Case Rep"},{"key":"R15-20261008","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/MBC.0000000000000879","article-title":"Bivalirudin anticoagulation to overcome heparin resistance in a neonate with cerebral sinovenus thrombosis.","volume":"31","author":"Bertamino","year":"2020","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R16-20261008","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/pbc.21731","article-title":"Bivalirudin for anticoagulation in children.","volume":"51","author":"Rayapudi","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20261008","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1111\/jth.13057","article-title":"UNBLOCK: An open-label, dose-finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis.","volume":"13","author":"O\u2019Brien","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"Suppl_1","key":"R18-20261008","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood.V130.Suppl_1.701.701","article-title":"Unfractionated heparin use in children: Clinical outcomes in a pediatric cohort managed using an anti-factor Xa based nomogram.","volume":"130","author":"Saini","year":"2017","journal-title":"Blood"},{"key":"R19-20261008","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1538-7836.2012.04624.x","article-title":"Unfractionated heparin dosing in young infants: Clinical outcomes in a cohort monitored with anti-factor Xa levels.","volume":"10","author":"Schechter","year":"2012","journal-title":"J Thromb Haemost"},{"key":"R20-20261008","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3324\/haematol.10616","article-title":"A clinically significant incidence of bleeding in critically ill children receiving therapeutic doses of unfractionated heparin: A prospective cohort study.","volume":"92","author":"Kuhle","year":"2007","journal-title":"Haematologica"},{"key":"R21-20261008","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1053\/j.jvca.2018.04.028","article-title":"Randomized controlled trial of heparin versus bivalirudin anticoagulation in acyanotic children undergoing open heart surgery.","volume":"32","author":"Hasija","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R22-20261008","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1053\/j.jvca.2022.04.044","article-title":"Bivalirudin anticoagulation in neonates and infants undergoing cardiac surgery.","volume":"36","author":"Hasija","year":"2022","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R23-20261008","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1203\/00006450-199401000-00016","article-title":"Heparin therapy in pediatric patients: A prospective cohort study.","volume":"35","author":"Andrew","year":"1994","journal-title":"Pediatr Res"},{"key":"R24-20261008","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1538-7836.2007.02623.x","article-title":"Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis.","volume":"5","author":"Young","year":"2007","journal-title":"J Thromb Haemost"},{"key":"R25-20261008","first-page":"671","article-title":"Pediatric catheterization laboratory anticoagulation with bivalirudin.","volume":"77","author":"Forbes","year":"2011","journal-title":"Catheter Cardiovasc Interv"},{"key":"R26-20261008","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/jth.12890","article-title":"Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.","volume":"13","author":"Trucco","year":"2015","journal-title":"J Thromb Haemost"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PCC.0000000000004029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:00:37Z","timestamp":1791468037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PCC.0000000000004029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000004029","relation":{},"ISSN":["1529-7535","1947-3893"],"issn-type":[{"value":"1529-7535","type":"print"},{"value":"1947-3893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}